Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $86
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $83 to $86.
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $83 to $86.